Full Length Research Paper
References
|
Ashour AA, Ahmed SA, Maghraby AS, Zahran HG (2004). Immunoprophylactic effect of single and mixed schistosomal antigens on Schistosoma mansoni infected mice. Egypt J. Hosp. Med. 14:86-103. |
|
|
Bergquist R, Utzinger J, McManus DP (2008). Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl. Trop. Dis. 2(6):e244. |
|
|
Boros DL, Warren KS (1970). Delayed hypersensitivity type III: granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from Schistosoma mansoni eggs. J. Exp. Med. 132(3):488-507. |
|
|
Boulanger D, Warter A, Sellin B, Lindner V, Pierce RJ, Chippaux JP, Capron A (1999). Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with a homologous challenge. Vaccine 17(4):319-326. |
|
|
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram qualities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:248-254. |
|
|
Carter CE, Collely DG (1979). Partial purification of Schistosoms mansoni soluble egg antigen with Con-Sepharase chromatography. J. Immunol. 122:2204-2209. |
|
|
Cheever AW (1968). Aquantitative post-mortem study of schistosomiasis mansoni in man. Am. J. Trop. Med. Hyg. 7(1):38-64. |
|
|
Chitsulo L, Loverde P, Engels D (2004). Schistosomiasis. Nat. Rev. Microbiol. 2(1):12–13. |
|
|
Doenhoff MJ, Pica-Mattoccia L (2006). Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev. Anti Infect. Ther. 4(2):199-210. |
|
|
Duvall RH, Dewitt WB (1967). An improved perfusion technique for recovering adult Schistosoma from laboratory animals. Am. J. Trop. Med. Hyg. 16(4):483–484. |
|
|
El-Ahwany E, Bauiomy IR, Nagy F, Zalat R, Mahmoud O, Zada S (2012). T Regulatory cell responses to immunization with a soluble egg antigen in Schistosoma mansoni-infected mice. Korean J. Parasitol. 50(1):29–35. |
|
|
El-Marhoumy SM, El-Nouby KA, Emara MA, Abou-Rayia DM (2009). An experimental study for evaluating the efficacy of cercarial vaccine against Schistosoma mansoni. J. Egypt Soc. Parasitol. 39(3):917-932. |
|
|
Fallon PG, Dunne DW (1999). Tolerization of mice to Schistosoma mansoni egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection. J. Immunol. 162(7):4122-4132. |
|
|
Gryseels BK, Clerinx PJ, Kestens L (2006). Human schistosomiasis. Lancet 368(9541):1106-1118. |
|
|
Himmelrich H, Lo-Man R, Winter N, Guermonprez P, Sedlik C, Rojas M, Monnaie D, Gheorghiu M, Lagranderie M, Hofnung M, Gicquel B, Clement JM, Leclerc C (2000). Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: malE. Vaccine 18(24):2636-2647. |
|
|
Hotez PJ, Engels D, Fenwick A, Savioli L (2010). Africa is desperate for praziquantel. Lancet 376(9740):496-498. |
|
|
Ismail OA (2005). Study of the efficacy of adult worm, cercarial and egg antigens in protection against experimental intestinal schistosomiasis. MD. Thesis. Faculty of Medicine, Suez Canal University. |
|
|
James CE, Hudson AL, Davey MW (2009). An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol. 25(12):538-547. |
|
|
Khalifa RMA, Elnadi NA, Omran EK, Abdel-Tawab RA (2011). Immunological response and the probability of production of vaccine for schistosome parasites. Egypt J. Med. Sci. 32(2):547-570. |
|
|
Lambertucci JR, Silva LC, Amaral RS (2007). Guidelines for the diagnosis and treatment of schistosomal myeloradiculopathy. Rev. Soc. Bras. Med. Trop. 40(5):574-581. |
|
|
Martin VP, Pinheiro CS, Figueiredo BCP, Assis NRG, Morais SB, Caliari MV, Azevedo V, Castro-Borges W, Wilson RA, Sergio C, Oliveira SC (2012). Vaccination with enzymatically cleaved GPI-Anchored proteins from Schistosoma mansoni induces protection against challenge infection. Clin. Dev. Immunol. 2012:962538. |
|
|
McManus DP, Loukas A (2008). Current Status of Vaccines for Schistosomiasis. Clin. Microbiol. Rev. 21(1):225-242. |
|
|
Nabih I, Soliman AM (1986). Studies on fresh water snails, specific intermediate host for schistosomiasis. II. Isolationof total protein from native and irradiated snails. Cell Mol. Biol. 32:315- 317. |
|
|
Nascimento E, Leão IC, Pereira VR, Gomes YM, Chikhlikar P, August T, Marques E, Lucena-Silva N (2002). Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis. Mem. Inst. Oswaldo Cruz 97 Suppl. 1:105-109. |
|
|
Ohara N, Yamada T (2001). Recombinant BCG vaccines. Vaccine 19:4089-4098. |
|
|
Pellegrino J, Oliveira CA, Faria J, Cunha AS (1962). New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am. J. Trop. Med. Hyg. 11:201-215. |
|
|
Peters AP, Warren KS (1969). A rapid method of infecting mice and other laboratory animals with Schistosoma mansoni subcutaneous injection. J. Parsitol. 55:558- 563. |
|
|
Salih SY, Bartlett A, Voller A (1978). Detection of antibodies by enzyme immunoassay in human schistosoma mansoni infections: a clinical and chemotherapeutic study. Tropenmed. Parasitol. 29(4):409-412. |
|
|
Siddiqui AA, Bilal A, Siddiqui,BA, Ganley-Leal L (2011). Schistosomiasis vaccines. Hum. Vaccin. 7(11):1192–1197. |
|
|
Smithers SR, Hackett F, Ali OP, Simpson AJG (1989). Protective immunization of mice against Schistosoma mansoni with purified adult worm surface membrane. Parasit. Immunol. 11:301-318. |
|
|
Soliman MF, El Shenawy NS, El Arabi SE (2008). Schistosoma mansoni: melatonin enhances efficacy of cercarial and soluble worm antigens in the induction of protective immunity against infection in the hamster. Exp. Parasitol. 119(2):291-295. |
|
|
Teixeira de Melo T, Michel de Araujo J, Do Valle Durães F, Caliari MV, Oliveira SC, Coelho PM, Fonseca CT (2010). Immunization with newly transformed Schistosoma mansoni schistosomula tegument elicits tegument damage, reduction in egg and parasite burden. Parasit. Immunol. 32(11-12):749-759. |
|
|
Tendler M, Pinto RM, Oliveira LA, Gebara G, Katz N (1986). Schistosoma mansoni: vaccination with adult worm antigens. Int. J. Parasitol. 16(4):347-352. |
|
|
Todd CW, Colley DG (2002). Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 66(4):348–358. |
|
|
Waine GJ, McManus DP (1999). Schistosomiasis vaccine development--the current picture. Bioassays 19(5):435-438. |
|
|
WHO (2000). Prospects for immunologic intervention in human schistosomiasis. 1-17 Technical Report Series, Geneva, Swizerland. |
|
|
WHO (2010). Schistosomiasis Fact Sheet N°115. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
